Treatment of Castleman disease from the perspective of the year 2026

Czech version

Authors: Z. Adam ¹; Z. Řehák ²; I. Boichuk ¹; T. Horváth ³; Z. Adamová ^4,5; M. Štork ¹; L. Pour ¹
Authors‘ workplace: Interní hematologická a onkologická klinika LF MU a FN Brno ¹; Oddělení nukleární medicíny, MOU Brno ²; Chirurgická klinika LF MU a FN Brno ³; Chirurgické oddělení, Nemocnice Frýdek-Místek ⁴; Chirurgické oddělení, Vsetínská nemocnice ⁵
Published in: Klin Onkol 2026; 39(2): 86-98
Category: Review
doi: https://doi.org/10.48095/ccko202686

Overview

Background: New drugs are continuously entering clinical practice, and therefore opinions on the treatment of Castleman disease are constantly being updated. The text provides information on the treatment of this disease from the perspective of the year 2026. Objective: The treatment of choice for unicentric Castleman disease is surgical removal of the lesion. If its size does not allow for surgery, preoperative pharmacological treatment may be used. There is less experience with radiotherapy in this indication. For multicentric Castleman disease (MCD), it is necessary to rule out possible but rarely detectable etiological causes, infection with human herpesvirus-8 (HHV-8), and association with POEMS syndrome. In HHV-8 positive cases, combinations of rituximab with cytostatics (liposomal doxorubicin, etoposide, or polychemotherapy) are used. In cases of MCD associated with POEMS syndrome, the aim of treatment is to suppress monoclonal gammopathy, which is considered the cause of both MCD and POEMS syndrome. Siltuximab is the treatment of choice for idiopathic multicentric Castleman disease (iMCD). It achieves a therapeutic response in less than 50% of unselected patients. If siltuximab treatment is administered only to patients with markedly elevated inflammatory markers, the number of therapeutic responses is higher. For patients who do not respond adequately to siltuximab, it is necessary to seek second -⁠ or third-line treatments. The efficacy of certain drugs in iMCD has been demonstrated not only through case reports but also in clinical studies (rituximab in combination with cytostatics, cyclophosphamide in combination with thalidomide or bortezomib, and sirolimus monotherapy). The efficacy of several other drugs has been shown through case reports or small patient series (anakinra, ruxolitinib, lenalidomide). Given the low incidence of the disease (3–5 per 1 million inhabitants), individual documented cases also provide valid guidance for treatment decisions. This text provides an overview of all experience with the treatment of this disease. Conclusion: The first-line treatment for iMCD is siltuximab. However, the disease has multiple etiopathogeneses, which is why siltuximab achieved disease symptom resolution in only half of the cases in an unselected population. For second -⁠ or third-line treatment, it is necessary to use one of the drugs with proven efficacy in iMCD.

Keywords:

sirolimus – rapamycin – bortezomib – Castleman disease – siltuximab – anakinra – rituximab – ruxolitinib – daratumab

Sources

1. van Rhee F, Oksenhendler E, Srkalovic G et al. International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease. Blood Adv 2020; 4 (23): 6039–6050. doi: 10.1182/bloodadvances.2020003334.

2. Horváth T, Frola L, Adam Z et al. Léčba unicentrické Castlemanovy choroby rituximabem, bendamustinem a dexametazonem zmenšila objem expanzivního ložiska v horním mediastinu a umožnila jeho radikální odstranění. Klin Onkol 2025; 38 (2): 132–143. doi: 10.48095/ccko2025132.

3. Penka I, Kala Z, Zetelová A et al. Castleman disease –⁠ surgical treatment. Case report. Rozhl Chir 2016; 95 (12): 457–461.

4. Melikyan AL, Egorova EK, Julhakyan HL et al. Human herpesvirus type 8-positive multicentric Castleman disease. Clin Lymphoma Myeloma Leuk 2016; 16 (Suppl): S159–S165. doi: 10.1016/j.clml.2016.03.009.

5. Kantarci FE, Eren R, Gündoğan C et al. A HHV-8 positive, HIV negative multicentric Castleman disease treated with R-CEOP chemotherapy and valganciclovir combination. J Infect Chemother 2016; 22 (7): 483–485. doi: 10.1016/j.jiac.2016.01.002.

6. Murphy C, Hawkes E, Chionh F et al. Durable remission of both multicentric Castleman‘s disease and Kaposi‘s sarcoma with valganciclovir, rituximab and liposomal doxorubicin in an HHV-8-positive, HIV-negative patient. J Clin Pharm Ther 2017; 42 (1): 111–114. doi: 10.1111/ jcpt.12472.

7. Osa M, Maeda T, Misawa K et al. Clinical response to liposomal doxorubicin and rituximab in HHV-8-associated multicentric Castleman‘s disease in an HIV-positive patient. J Infect Chemother 2016; 22 (12): 804–807. doi: 10.1016/j.jiac.2016.06.004.

8. Uldrick TS, Polizzotto MN, Aleman K et al. Rituximab plus liposomal doxorubicin in HIV-infected patients with KSHV-associated multicentric Castleman disease. Blood 2014; 124 (24): 3544–3552. doi: 10.1182/blood-2014-07-586800.

9. Rasmussen C, Gérard L, Fadlallah J et al. Higher rate of progression in HIV -⁠ than in HIV+ patients after rituximab for HHV8+ multicentric Castleman disease. Blood Adv 2023; 7 (18): 5663–5669. doi: 10.1182/bloodadvances.2023010316.

10. Min C, Liu A, Xu Y et al. A case report of Castleman disease variant of POEMS syndrome presenting with prominent polyserositis and renal impairment. Front Med (Lausanne) 2025; 12 : 1537944. doi: 10.3389/fmed.2025.1537944.

11. Sevindik OG, Mutlu YG, Aydin BB et al. First-line usage of daratumumab, lenalidomide, dexamethasone (DRd) combination in a case of Castleman disease variant of polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes syndrome (CD-POEMS). Hemasphere 2022; 6 (7): e728. doi: 10.1097/HS9.0000000000000728.

12. Lee YM, Choi YS, Kim JM. POEMS syndrome: presented as idiopathic multicentric Castleman disease of plasma cell variant for eight years and dramatic treatment with siltuximab followed by autologous peripheral blood stem cell transplantation. Diagnostics (Basel) 2022; 12 (4): 998. doi: 10.3390/diagnostics12040998.

13. Haider SA, Iram S, Rashid AA et al. POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal plasma cell disorder, and skin changes) syndrome as a sequela of Castleman disease: a case report. Cureus 2023; 15 (11): e49330. doi: 10.7759/cureus.49330.

14. Rodriguez-Merino L, Montes-Moreno S. Castleman disease-type histopathological patterns of lymph nodes in patients with plasma cell neoplasia and POEMS syndrome. Ann Diagn Pathol 2025; 74 : 152414. doi: 10.1016/j.anndiagpath.2024.152414.

15. Milota T, Střížová Z, Sobotková M et al. The role of interleukin 6 in the pathogenesis and therapy of Castleman disease –⁠ an immunologist’s perspective. Cas Lek Cesk 2023; 162 (2–3): 106–111.

16. Ferrero S, Ragaini S. Dichotomic response to interleukin-6 blockade in idiopathic multicentric Castleman disease: two case reports. J Med Case Rep 2021; 15 (1): 105. doi: 10.1186/s13256-021-02726-4.

17. van Rhee F, Voorhees P, Dispenzieri A et al. International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood 2018; 132 (20): 2115–2124. doi: 10.1182/blood-2018-07-862334.

18. Lukáč M, Khor J, Coren F et al. Register ACCELERATE: využitie inovatívnej metódy pri výskume Castlemanovej choroby. Klin Farmakol Farm 2021; 35 (3): 87–95.

19. Nikanjam M, Yang J, Capparelli EV. Population pharmacokinetics of siltuximab: impact of disease state. Cancer Chemother Pharmacol 2019; 84 (5): 993–1001. doi: 10.1007/s00280-019-03939-7.

20. van Rhee F, Fayad L, Voorhees P et al. Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman‘s disease. J Clin Oncol 2010; 28 (23): 3701–3708. doi: 10.1200/JCO.2009.27.2377.

21. Van Rhee F, Wong RS, Munshi N et al. Siltuximab for multicentric Castleman‘s disease. A randomized double blind placebo controlled trial. Lancet Oncol 2014; 15 (9): 966–974. doi: 10.1016/S1470-2045 (14) 70319-5.

22. van Rhee F, Casper C, Voorhees PM et al. A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease. Oncotarget 2015; 6 (30): 30408–30419. doi: 10.18632/oncotarget.4655.

23. van Rhee F, Rossi JF, Simpson D et al. Newly diagnosed and previously treated multicentric Castleman disease respond equally to siltuximab. Br J Haematol 2021; 192 (1): e28–e31. doi: 10.1111/bjh.17177.

24. van Rhee F, Casper C, Voorhees PM et al. Long-term safety of siltuximab in patients with idiopathic multicentric Castleman disease: a prespecified, open-label, extension analysis of two trials. Lancet Haematol 2020; 7 (3): e209–e217. doi: 10.1016/S2352-3026 (19) 30257-1.

25. van Rhee F, Rosenthal A, Kanhai K et al. Siltuximab is associated with improved progression-free survival in idiopathic multicentric Castleman disease. Blood Adv 2022; 6 (16): 4773–4781. doi: 10.1182/bloodadvances.2022007112.

26. Lang E, Sande B, Brodkin S et al. Idiopathic multicentric Castleman disease treated with siltuximab for 15 years: a case report. Ther Adv Hematol 2022; 13 : 20406207221082552. doi: 10.1177/20406207221082552.

26. Gao YH, Li J, Zhang L et al. Rapid relapse of idiopathic multicentric Castleman disease after siltuximab discontinuation in a case with complete remission for more than 10 years. Turk J Haematol 2024; 41 (4): 283–285. doi: 10.4274/tjh.galenos.2024.2024.0339.

28. Tonialini L, Bonfichi M, Ferrero S et al. Siltuximab in relapsed/refractory multicentric Castleman disease: experience of the Italian NPP program. Hematol Oncol 2018; 36 (4): 689–692. doi: 10.1002/hon.2532.

29. Rossini B, Cecchi N, Clemente F et al. Real-practice management and treatment of idiopathic multicentric Castleman disease with siltuximab: a collection of clinical experiences. Drugs Context 2024; 13 : 2023-9-4. doi: 10.7573/dic.2023-9-4.

30. Ostrowska B, Szymczyk A, Olszewska-Szopa M et al. Efficacy of siltuximab in the treatment of idiopathic multicentric Castleman disease, the first Polish, real-world experience with long-term observation. Leuk Lymphoma 2021; 62 (12): 3031–3034. doi: 10.1080/10428194.2021.1941926.

31. Jitaru C, Symeonidis A, Badelita S et al. Siltuximab in idiopathic multicentric Castleman disease: real-world experience. J Hematol 2024; 13 (5): 207–215. doi: 10.14740/jh1343.

32. Li SY, Gao YH, Dang Y et al. Real-world data of siltuximab for Chinese patients with iMCD: combination with BCD regimen as a potential approach for severe cases. Ann Hematol 2025; 104 (3): 1713–1720. doi: 10.1007/s00277-025-06329-7.

33. Pierson SK, Lim MS, Srkalovic G et al. Treatment consistent with idiopathic multicentric Castleman disease guidelines is associated with improved outcomes. Blood Adv 2023; 7 (21): 6652–6664. doi: 10.1182/bloodadvances.2023010745.

34. Morra DE, Pierson SK, Shilling D et al. Predictors of response to anti-IL6 monoclonal antibody therapy (siltuximab) in idiopathic multicentric Castleman disease: secondary analyses of phase II clinical trial data. Br J Haematol 2019; 184 (2): 232–241. doi: 10.1111/bjh.15588.

35. Pierson SK, Katz L, Williams R et al. CXCL13 is a predictive biomarker in idiopathic multicentric Castleman disease. Nat Commun 2022; 13 (1): 7236. doi: 10.1038/s41467-022-34873-7.

36. Adam Z, Zeman D, Chodacki A et al. Therapy of Castleman’s disease with siltuximab –⁠ case report and review of literature. Klin Onkol 2023; 36 (4): 320–329.

37. Adam Z, Pour L, Zeman D et al. Castlemanova choroba, plazmocelulární varianta (příčina dlouhodobě zvýšených zánětlivých markerů u mladé ženy a léčebné možnosti při snaze o zachování fertility). Med Umění 2022; 5 (73): 33–39.

38. Moreau J, Leurs A, Ledoult E et al. Siltuximab as a salvage therapy in multi-refractory adult-onset Still‘s disease: a case series. Rev Med Interne 2025; 46 (7): 415–420. doi: 10.1016/j.revmed.2025.05.002.

39. Cáceres-Nazario B, Rivenbark J, Saha MK et al. Novel use of siltuximab in a patient with VEXAS Syndrome. Ann Hematol 2025; 104 (2): 1259–1267. doi: 10.1007/s00277-024-06037-8.

40. Ocio EM, Sanchez-Guijo FM, Diez-Campelo M et al. Efficacy of rituximab in an aggressive form of multicentric Castleman disease associated with immune phenomena. Am J Hematol 2005; 78 (4): 302–305. doi: 10.1002/ajh.20283.

41. Jain P, Verstovsek S, Loghavi S et al. Durable remission with rituximab in a patient with an unusual variant of Castleman‘s disease with myelofibrosis-TAFRO syndrome. Am J Hematol 2015; 90 (11): 1091–1092. doi: 10.1002/ajh.24015.

42. Ramasamy K, Gandhi S, Tenant-Flowers M et al. Rituximab and thalidomide combination therapy for Castleman disease. Br J Haematol 2012; 158 (3): 421–423. doi: 10.1111/j.1365-2141.2012.09157.x.

43. Zhu L, Liu Y, Yu F et al. Successful treatment of idiopathic multicentric Castleman disease with rash as the initial symptom using a rituximab-based regimen. J Hematol 2024; 13 (5): 245–249. doi: 10.14740/jh1313.

44. Dong Y, Zhang L, Nong L et al. Effectiveness of rituximab-containing treatment regimens in idiopathic multicentric Castleman disease. Ann Hematol 2018; 97 (9): 1641–1647. doi: 10.1007/s00277-018-3347-0.

45. Yin X, Liu Y, Zhong C et al. Rituximab-bortezomib-dexamethasone induce high response rates in iMCD in clinical practice. Br J Haematol 2023; 203 (5): 803–806. doi: 10.1111/bjh.19000.

46. Rehman MEU, Chattaraj A, Neupane K et al. Efficacy and safety of regimens used for the treatment of multicentric Castleman disease: a systematic review. Eur J Haematol 2022; 109 (4): 309–320. doi: 10.1111/ejh.13823.

47. Gérard L, Michot JM, Burcheri S et al. Rituximab decreases the risk of lymphoma in patients with HIV-associated multicentric Castleman disease. Blood 2012; 119 (10): 2228–2233. doi: 10.1182/blood-2011-08-376012.

48. Servati S, Mohammadi I, Rajai Firouzabadi S. First-line treatment of TAFRO syndrome with rituximab: a case report and literature review. Ann Hematol 2025; 104 (5): 3035–3046. doi: 10.1007/s00277-025-06327-9.

49. Adam Z, Szturz P, Krejčí M et al. Treatment of 14 cases of Castleman’s disease: the experience of one centre and an overview of literature. Vnitr Lek 2016; 62 (4): 287–298.

50. Adam Z, Szturz P, Koukalová R et al. PET-CT documented remission of multicentric Castleman disease after treatment with rituximab: case report and review. Vnitr Lek 2015; 61 (3): 251–259.

51. Szturz P, Sedivá A, Zurek M et al. Anakinra treatment in Schnitzler syndrome –⁠ results of the first retrospective multicenter study in six patients from the Czech Republic. Klin Onkol 2014; 27 (2): 111–126. doi: 10.14735/amko2014111.

52. Adam Z, Král Z, Řehák Z et al. Léčba Stillovy nemoci vzniklé v dospělosti anakinrou. Farmakoter Rev 2024; 9 (3): 227–232.

53. Adam Z, Šedivá A, Zeman D et al. Successful treatment of SAPHO syndrome (chronic nonbacterial osteomyelitis and acne) with anakinra and denosumab. Case report and review of therapy. Vnitr Lek 2023; 69 (5): E4–E14. doi: 10.36290/vnl.2023.065.

54. Galeotti C, Tran TA, Franchi-Abella S et al. IL-1RA agonist (anakinra) in the treatment of multifocal Castleman disease: case report. J Pediatr Hematol Oncol 2008; 30 (12): 920–924. doi: 10.1097/MPH.0b013e31818ab31f.

55. El-Osta H, Janku F, Kurzrock R. Successful treatment of Castleman‘s disease with interleukin-1 receptor antagonist (Anakinra). Mol Cancer Ther 2010; 9 (6): 1485–1488. doi: 10.1158/1535-7163.MCT-10-0156.

56. Jouvray M, Terriou L, Meignin V et al. Pseudo-adult Still‘s disease, anasarca, thrombotic thrombocytopenic purpura and dysautonomia: an atypical presentation of multicentric Castleman‘s disease. Discussion of TAFRO syndrome. Rev Med Interne 2016; 37 (1): 53–57. doi: 10.1016/j.revmed.2015.04.006.

57. Soudet S, Fajgenbaum D, Delattre C et al. Schnitzler syndrome co-occurring with idiopathic multicentric Castleman disease that responds to anti-IL-1 therapy: a case report and clue to pathophysiology. Curr Res Transl Med 2018; 66 (3): 83–86. doi: 10.1016/j.retram.2018.06.001.

58. Borocco C, Ballot-Schmit C, Ackermann O et al. The French paediatric cohort of Castleman disease: a retrospective report of 23 patients. Orphanet J Rare Dis 2020; 15 (1): 95. doi: 10.1186/s13023-020-1345-5.

59. Lanzillotta M, Sant’Angelo M, Kaneko N et al. Treating life-threatening TAFRO syndrome with interleukin-1 inhibition. Eur J Intern Med 2021; 87 : 121–123. doi: 10.1016/j.ejim.2021.02.006.

60. Palmeri S, Ferro J, Natoli V et al. Efficacy of high-dose intravenous anakinra in pediatric TAFRO syndrome: report of two cases and literature review. Pediatr Blood Cancer 2025; 72 (8): e31759. doi: 10.1002/pbc.31759.

61. Mumau MD, Gonzalez MV, Ma C et al. Identifying and targeting TNF signaling in idiopathic multicentric Castleman‘s disease. N Engl J Med 2025; 392 (6): 616–618. doi: 10.1056/NEJMc2412494.

62. Bogoczová E, Čičátková P, Palová M et al. Zkušenosti s léčbou ruxolitinibem u pacientů s myelofibrózou a pravou polycytemií na českých hematologických pracovištích. Trans Hematol Dnes 2017; 23 (1): 30–40.

63. Lust H, Gong S, Remiker A et al. Idiopathic multicentric Castleman disease with TAFRO clinical subtype responsive to IL-6/JAK inhibition: a pediatric case series. Pediatr Blood Cancer 2021; 68 (10): e29261. doi: 10.1002/pbc.29261.

64. Killian M, Viel S, Chalayer E et al. JAK1/2 inhibition in severe TAFRO syndrome: a case report. Ann Intern Med 2021; 174 (5): 719–721. doi: 10.7326/L20-1051.

65. Kakutani T, Nunokawa T, Chinen N et al. Treatment-resistant idiopathic multicentric Castleman disease with thrombocytopenia, anasarca, fever, retikulin fibrosis, renal dysfunction, and organomegaly managed with Janus kinase inhibitors: a case report. Medicine (Baltimore) 2022; 101 (48): e32200. doi: 10.1097/MD.0000000000032200.

66. Gao YH, Duan MH, Li J et al. Ruxolitinib for the treatment of refractory idiopathic multicentric Castleman disease: a case report. Turk J Haematol 2024; 41 (1): 61–63. doi: 10.4274/tjh.galenos.2024.2023.0477.

67. Doubková M, Štefánková M, Čan V et al. Lymphangioleiomyomatosis. Klin Onkol 2019; 32 (5): 367–374. doi: 10.14735/amko2019367.

68. Ozeki M, Endo S, Yasue S et al. Sirolimus treatment for intractable vascular anomalies (SIVA): an open-label, single-arm, multicenter, prospective trial. Pediatr Int 2025; 67 (1): e70002. doi: 10.1111/ped.70002.

69. Wiegand S, Dietz A, Wichmann G. Efficacy of sirolimus in children with lymphatic malformations of the head and neck. Eur Arch Otorhinolaryngol 2022; 279 (8): 3801–3810. doi: 10.1007/s00405-022-07378-8.

70. Seront E, Van Damme A, Legrand C et al. Preliminary results of the European multicentric phase III trial regarding sirolimus in slow-flow vascular malformations. JCI Insight 2023; 8 (21): e173095. doi: 10.1172/jci.insight.173095.

71. Seront E, Hermans C, Boon LM et al. Targeted treatments for vascular malformations: current state of the art. J Thromb Haemost 2024; 22 (11): 2961–2975. doi: 10.1016/j.jtha.2024.07.013.

72. Durán-Romero AJ, Hernández-Rodríguez JC, Ortiz-Álvarez J et al. Efficacy and safety of oral sirolimus for high-flow vascular malformations in real clinical practice. Clin Exp Dermatol 2022; 47 (1): 57–62. doi: 10.1111/ced.14841.

73. Blagosklonny MV. Cancer prevention with rapamycin. Oncotarget 2023; 14 : 342–350. doi: 10.18632/oncotarget.28410.

74. Gao H, Liu S, Mai Y et al. Combined therapy of prednisone and mTOR inhibitor sirolimus for treating retroperitoneal fibrosis. Ann Rheum Dis 2023; 82 (5): 688–697. doi: 10.1136/ard-2022-223736.

75. Fiamoli V, Blatný J, Pejchalová A et al. Sirolimus –⁠ alternativa pro léčbu autoimunitní hemolytické anémie způsobené tepelnými protilátkami (WAIHA). Trans Hematol Dnes 2019; 25 (3): 264–268.

76. Arenas DJ, Floess K, Kobrin D et al. Increased mTOR activation in idiopathic multicentric Castleman disease. Blood 2020; 135 (19): 1673–1684. doi: 10.1182/blood.2019002792.

77. Pierson SK, Shenoy S, Oromendia AB et al. Discovery and validation of a novel subgroup and therapeutic target in idiopathic multicentric Castleman disease. Blood Adv 2021; 5 (17): 3445–3456. doi: 10.1182/bloodadvances.2020004016.

78. Stern RM, Berliner N. Targeting the mTOR pathway in idiopathic multicentric Castleman disease. J Clin Invest 2019; 129 (10): 4086–4088. doi: 10.1172/JCI131332.

79. Fajgenbaum DC, Langan RA, Japp AS et al. Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6-blockade-refractory idiopathic multicentric Castleman disease. J Clin Invest 2019; 129 (10): 4451–4463. doi: 10.1172/JCI126091.

80. Bevacqua M, Baldo F, Pastore S et al. Sirolimus and everolimus in a pediatric center: a case series and review of the literature. Paediatr Drugs 2019; 21 (3): 185–193. doi: 10.1007/s40272-019-00337-7.

81. Sumiyoshi R, Koga T, Furukawa K et al. A case of tocilizumab-refractory idiopathic multicentric Castleman‘s disease successfully treated with sirolimus. Clin Immunol 2021; 233 : 108887. doi: 10.1016/j.clim.2021. 108887.

82. Bayram E, Pehlivan UA, Fajgenbaum DC et al. Refractory idiopathic multicentric Castleman disease responsive to sirolimus therapy. Am J Hematol 2023; 98 (2): 361–364. doi: 10.1002/ajh.26783.

83. Liu YT, Gao YH, Zhao H et al. Sirolimus is effective for refractory/relapsed idiopathic multicentric Castleman disease: a single-center, retrospective study. Ann Hematol 2024; 103 (10): 4223–4230. doi: 10.1007/s00277-024-05783-z.

84. Koga T, Takemori S, Hagimori N et al. An open-label continuation trial of sirolimus for tocilizumab-refractory idiopathic multicentric Castleman disease: study protocol for an investigator-initiated, multicenter, open-label trial (SPIRIT compliant). Medicine (Baltimore) 2020; 99 (50): e23291. doi: 10.1097/MD.0000000000023291.

85. Wang X, Ye S, Xiong C et al. Successful treatment with bortezomib and thalidomide for POEMS syndrome associated with multicentric mixed-type Castleman‘s disease. Jpn J Clin Oncol 2011; 41 (10): 1221–1224. doi: 10.1093/jjco/hyr120.

86. Lin Q, Fang B, Huang H et al. Efficacy of bortezomib and thalidomide in the recrudescent form of multicentric mixed-type Castleman‘s disease. Blood Cancer J 2015; 5 (3): e298. doi: 10.1038/bcj.2015.12.

87. Miltenyi Z, Toth J, Gonda A et al. Successful immunomodulatory therapy in Castleman disease with paraneoplastic pemphigus vulgaris. Pathol Oncol Res 2009; 15 (3): 375–381. doi: 10.1007/s12253-008-9133-x.

88. Jung CP, Emmerich B, Goebel FD et al. Successful treatment of a patient with HIV-associated multicentric Castleman disease (MCD) with thalidomide. Am J Hematol 2004; 75 (3): 176–177. doi: 10.1002/ajh.10467.

89. Starkey CR, Joste NE, Lee FC. Near-total resolution of multicentric Castleman disease by prolonged treatment with thalidomide. Am J Hematol 2006; 81 (4): 303–304. doi: 10.1002/ajh.20538.

90. Tatekawa S, Umemura K, Fukuyama R et al. Thalidomide for tocilizumab-resistant ascites with TAFRO syndrome. Clin Case Rep 2015; 3 (6): 472–478. doi: 10.1002/ccr3.284.

91. Zhang L, Zhao AL, Duan MH et al. Phase 2 study using oral thalidomide-cyclophosphamide-prednisone for idiopathic multicentric Castleman disease. Blood 2019; 133 (16): 1720–1728. doi: 10.1182/blood-2018-11-884577.

92. Adam Z, Szturz P, Křen L et al. PET-CT documented fast onset of treatment response to cyclophosphamide, thalidomide and dexamethasone in patients with multicentric Castlemans disease. Case description and treatment information overview. Vnitr Lek 2013; 59 (4): 301–312.

93. Adam Z, Klimeš J, Pour L et al. Maligní onemocnění psychika a stres. Praha: Grada Publishing 2021.

94. Zhou X, Wei J, Lou Y et al. Salvage therapy with lenalidomide containing regimen for relapsed/refractory Castleman disease: a report of three cases. Front Med 2017; 11 (2): 287–292. doi: 10.1007/s11684-017-0510-2.

95. Cai S, Zhong Z, Li X et al. Treatment of multicentric Castleman disease through combination of tocilizumab, lenalidomide and glucocorticoids: case report. Medicine (Baltimore) 2019; 98 (46): e17681. doi: 10.1097/MD.0000000000017681.

96. Zhang Y, Suo SS, Yang HJ et al. Clinical features and treatment of 7 Chinese TAFRO syndromes from 96 de novo Castleman diseases: a 10-year retrospective study. J Cancer Res Clin Oncol 2020; 146 (2): 357–365. doi: 10.1007/s00432-019-03120-w.

97. Szturz P, Adam Z, Chovancová J et al. Lenalidomide: a new treatment option for Castleman disease. Leuk Lymphoma 2012; 53 (10): 2089–2091. doi: 10.3109/10428194.2011.621564.

98. Szturz P, Adam Z, Moulis M et al. Our experience in treatment of multicentric plasma-cell Castleman disease associated with vasculitis manifestations –⁠ case report and literature review. Vnitr Lek 2012; 58 (9): 679–690.

99. Sevindik OG, Mutlu YG, Aydin BB et al. Usage of daratumumab, lenalidomide, dexamethasone (DRd) combination in a case of Castleman disease variant of polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes syndrome (CD-POEMS). Hemasphere 2022; 6 (7): e728. doi: 10.1097/HS9.0000000000000728.

100. Shi Y, Li J, Zhang L. Daratumumab for the treatment of refractory idiopathic multicentric Castleman disease: a case report. Ann Hematol 2022; 101 (11): 2529–2531. doi: 10.1007/s00277-022-04926-4.

101. Coulomb D, Szablewski V, Robert N et al. A case of refractory IgG4-related disease successfully treated with daratumumab and lenalidomide. Rheumatology (Oxford) 2025; 64 (2): 895–897. doi: 10.1093/rheumatology/keae448.

102. Peng Q, Wu F, Shi Y et al. Idiopathic multicentric Castleman‘s disease mimicking immunoglobulin G4-related disease responding well to bortezomib: a case report. BMC Nephrol 2023; 24 (1): 290. doi: 10.1186/s12882-023-03335-7.

103. Khan AA, Siraj F, Bhargava M et al. Successful treatment of multicentric Castleman‘s disease accompanying myeloma with bortezomib. BMJ Case Rep 2012; 2012: bcr2012007646. doi: 10.1136/bcr-2012-007646.

104. Liu XH, Zhang L, Li J et al. Rare forms of idiopathic multicentric Castleman disease presenting with intrahepatic cholestatic jaundice successfully treated with the bortezomib-based regimen: two case reports. Ann Hematol 2023; 102 (4): 977–979. doi: 10.1007/s00277-022-05066-5.

105. Lin Q, Fang B, Huang H et al. Efficacy of bortezomib and thalidomide in the recrudescent form of multicentric mixed-type Castleman‘s disease. Blood Cancer J 2015; 5 (3): e298. doi: 10.1038/bcj.2015.12.

106. Zhang L, Zhang MY, Cao XX et al. A prospective, multicenter study of bortezomib, cyclophosphamide, and dexamethasone inrelapsed/refractory iMCD. Leuk Lymphoma 2022; 63 (3): 618–626. doi: 10.1080/10428194.2021.1999437.

107. Gao YH, Li SY, Dang Y et al. Efﬁcacy and safety of orelabrutinib in relapsed/refractory idiopathic multicentric Castleman disease: a single-centre, retrospective study. Br J Haematol 2025; 206 (1): 152–158. doi: 10.1111/bjh.19827.

108. Zhang L, Gao YH, Li SY et al. A prospective study of zanubrutinib, a Bruton tyrosine kinase inhibitor, in relapsed/refractory idiopathic multicentric Castleman disease. Int J Hematol 2024; 119 (6): 631–637. doi: 10.1007/s12185-024-03747-7.

109. Frampton JE. Inebilizumab: first approval. Drugs 2020; 80 (12): 1259–1264. doi: 10.1007/s40265-020-01370-4.

110. Nie T, Blair HA. Inebilizumab: a review in neuromyelitis optica spectrum disorder. CNS Drugs 2022; 36 (10): 1133–1141. doi: 10.1007/s40263-022-00949-7.

111. Stone JH, Khosroshahi A, Zhang W et al. Inebilizumab for treatment of IgG4-related disease. N Engl J Med 2025; 392 (12): 1168–1177. doi: 10.1056/NEJMoa240 9712.

112. Li S, Gao Y, He Y et al. A case report of AQP4-IgG-seropositive refractory neuromyelitis optica spectrum disorder patient with Sjögren‘s syndrome and pancytopenia treated with inebilizumab. Front Neurol 2024; 15 : 1371515. doi: 10.3389/fneur.2024.1371515.

113. Koa B, Borja AJ, Aly M et al. Emerging role of 18F-FDG PET/CT in Castleman disease: a review. Insights Imaging 2021; 12 (1): 35. doi: 10.1186/s13244-021-00963-1.

114. Koukalová R, Selingerová I, Řehák Z et al. FDG -⁠ -PET/ CT for initial staging and response assessment in Castleman disease –⁠ retrospective single-center study of 29 cases. Klin Onkol 2021; 34 (2): 120–127. doi: 10.48095/ccko2021120.

115. Bitektine E, Hagh-Daoust H, Michel RP et al. The value of a pet scan in selecting the best lymph node to biopsy, and confirming the diagnosis of idiopathic multicentric Castleman disease with HLH and EBV viremia in a previously healthy adult. Eur J Case Rep Intern Med 2024; 11 (12): 004908. doi: 10.12890/2024_ 004908.

116. Han EJ, O JH, Jung SE et al. FDG PET/CT findings of Castleman disease assessed by histologic subtypes and compared with laboratory findings. Diagnostics (Basel) 2020; 10 (12): 998. doi: 10.3390/diagnostics10 120998.

117. Wang G, Xu Q, Liu Y et al. 18F-FDG PET/CT metabolic parameters are correlated with clinical features and valuable in clinical stratification management in patients of Castleman disease. Cancer Imaging 2025; 25 (1): 12. doi: 10.1186/s40644-025-00833-9.

118. Nishimura Y, Habermann T, Dispenzieri A. Comparative safety of tocilizumab and siltuximab in Castleman disease: pharmacovigilance study. Am J Hematol 2025; 101 (1): 165–168. doi: 10.1002/ajh.70122.